
Free Daily Podcast Summary
by KAMI Think Tank
At KAMI Think Tank, we love cutting through the AI hype to showcase where the technology actually stands and how to use it meaningfully within the life sciences. Now, we're bringing that same clarity with our community to a brand new podcast: From Models to Medicine. Every week, we sit down with a real practitioner in the life sciences, whether they're working in the lab, leading innovation at a biotech, or building tools to better serve scientists. We discuss how they cut through the hype of AI and practically leverage the tool in their scientific workflows. Glad to have you here.
The most recent episodes — sign up to get AI-powered summaries of each one.
In this episode of From Models to Medicine, we sit down with Minna Schmidt, a postdoctoral researcher at the Buck Institute for Research on Aging. Minna walks us through Braak's hypothesis and the emerging "brain-first vs. body-first" framing of the disease, explaining how symptoms can appear up to 30 years before a clinical diagnosis is ever made. We also get into the data side of the work. Minna uses a dataset with over 54,000 participants and talks honestly about what AI actually does and doesn't unlock when you're staring down that volume of microbiome and clinical data. She uses LLMs to organize her thinking, speed up literature reviews, and learn basic programming, while being clear-eyed about where the field's biggest bottleneck actually is: not the tools, but the data itself. ----------------------------------------------------------------------This episode was sponsored by CleanSpace. CleanSpace designs, manufactures, and installs advanced controlled environments—delivering complex projects months faster with guaranteed costs and uncompromising performance. Please contact Chelsea for more information or with any questions at CLauridsen@CleanSpaceus.com.
In this episode of From Models to Medicine, we sit down with Sal Tejani, Associate Director for Field Medical Affairs at Regeneron*, who started his career catching dangerous prescription errors at CVS and never lost the instinct for finding the lever that actually moves things. Today that instinct is pointed squarely at AI; how to use it, when to trust it, and when it will absolutely get you into trouble.Sal gives us an honest, practitioner-level view of what AI looks like inside a major pharma company: the tools that are actually useful, the guardrails that are non-negotiable, and the human judgment that no model has figured out how to replace yet. Plus, he closes with a personal story that reframes the whole conversation about why any of this actually matters.This episode was sponsored by CleanSpace. CleanSpace designs, manufactures, and installs advanced controlled environments—delivering complex projects months faster with guaranteed costs and uncompromising performance. Please contact Chelsea for more information or with any questions at CLauridsen@CleanSpaceus.com. *Thoughts brought up on this podcast do not represent the views of Regeneron.
Rachel Jacobson has spent her career moving between some of the most demanding corners of life sciences before founding Powerhouse Biology. In this episode, she traces that journey and explains why, after all of it, she keeps coming back to mitochondria. We get into what it actually takes to bridge biology and machine learning inside a lab culture, why asking "stupid questions" across disciplines is a feature and not a bug, and what she had to unlearn from traditional drug development to work effectively alongside ML engineers.We also dig into data design. Rachel makes a sharp case that data passing standard biological QC is not the same as data that's ready for a machine learning model. Uneven plate layouts, cell debris, different scientists handling samples can all create batch effects that quietly break your model before it ever sees a hypothesis worth testing. She connects all of this to a bigger argument about why human biological variability needs to be built into preclinical pipelines from the start, and why ML might finally give scientists the tools to do that seriously.
In this episode, we sit down with Dr. Freddy Nguyen, CEO and co-founder of Nine Diagnostics, whose background spans medicine, pathology, optics, and nanotechnology. Freddy shares how Nine Diagnostics is building a multiomics platform that helps cancer patients find out within days whether their treatment is actually working. We dig into why AI's real power in medicine lies in its ability to connect siloed data across molecular readouts, imaging, and clinical context, and why treating patients as more than just their diagnosis is the only way to build tools that actually hold up in the real world. We also get into the harder conversation: where AI in clinical workflows breaks down. It's a candid, technically grounded conversation about what equitable AI in medicine actually requires.
In this episode of From Models to Medicine, we sit down with Elisa Martin Perez, a postdoc at University of California, Berkeley, to talk about how non-coders are starting to use AI in their day-to-day work. From learning R through conversation to making sense of massive CRISPR screens, Elisa shares how AI is becoming a practical tool for navigating data, checking experimental design, and cutting down on the kinds of manual tasks that quietly consume hours in the lab.We also get into the hesitation many scientists feel around adopting AI, where the technology actually helps (and where it doesn’t), and why it still falls short of running experiments end-to-end. Along the way, we touch on lab logistics, data overload, and what it means to use AI as a thinking partner rather than a replacement.
What does it actually take to make AI work inside a pharmaceutical company and why do so many efforts stall after the model is built? Pranay Mohanty, from J&J Innovative Medicine, joins us to talk about how building the model is only one part of the work and what can happen when you try to apply that model to messy, real-world data.We dig into how teams are starting to use digital twins to simulate patients and rethink trial design, what it looks like to work alongside regulators like the U.S. Food and Drug Administration, and why keeping a human in the loop isn’t optional. Along the way, we share how AI is actually shaping portfolio decisions today and where the limits still are.
In this episode of From Models to Medicine, we sit down with Ashley Zehnder, the founder of Fauna Bio to explore one of the most creative bets in drug discovery: using extreme animal biology to unlock human therapeutics. We dig into the graph neural networks powering Fauna Bio's drug discovery platform, the unglamorous data curation work that makes it all function, and why human-in-the-loop isn't a limitation but a design principle. Plus: what hibernation research could mean for long-duration human space travel.
What does emergency medicine have to do with large-scale knowledge systems? Jason Grafft joins us to talk about his non-linear path from EMS and simulation education to knowledge engineering and why the structured, fact-bound thinking that medicine demands is one of the most undervalued assets in the AI era. We dig into how he uses graph-based models to bridge clinical experts and technical systems, where LLMs are actually helping in entity resolution, and the practical advice he gives every clinician trying to break into tech.
At KAMI Think Tank, we love cutting through the AI hype to showcase where the technology actually stands and how to use it meaningfully within the life sciences. Now, we're bringing that same clarity with our community to a brand new podcast: From Models to Medicine. Every week, we sit down with a real practitioner in the life sciences, whether they're working in the lab, leading innovation at a biotech, or building tools to better serve scientists. We discuss how they cut through the hype of AI and practically leverage the tool in their scientific workflows. Glad to have you here.
AI-powered recaps with compact key takeaways, quotes, and insights.
Get key takeaways from From Models to Medicine in a 5-minute read.
Stay current on your favorite podcasts without falling behind.
It's a free AI-powered email that summarizes new episodes of From Models to Medicine as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by KAMI Think Tank.
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
From Models to Medicine publishes weekly. Our AI generates a summary within hours of each new episode.
Our AI identifies the specific themes in each episode and highlights what matters most to you.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.